Cholinergic agonists are drugs that mimic or amplify the effects of acetylcholine, the chemical messenger your nervous system uses to control everything from muscle contraction to gland secretion to certain brain functions. Some of these drugs activate acetylcholine receptors directly, while others work by preventing the body from breaking acetylcholine down, effectively raising its levels at the synapse. The family spans an enormous range of uses, from shrinking your pupils during an eye exam to slowing cognitive decline in Alzheimer’s disease, and the side effects they produce follow logically from the same biology that makes them useful.
Direct Versus Indirect Agonists
The most important distinction in this drug class is between direct-acting and indirect-acting agents. Direct-acting cholinergic agonists bind to acetylcholine receptors and switch them on, behaving like a spare key that fits the same lock acetylcholine does. Indirect-acting agents take a different approach: they block acetylcholinesterase, the enzyme responsible for breaking acetylcholine down after it has done its job. By keeping that enzyme out of commission, indirect agents let acetylcholine accumulate and linger at the receptor longer than it normally would.1PubMed. Cholinergic Medications
This distinction matters clinically because the two strategies produce different pharmacological profiles. A direct agonist hits whichever receptor subtype it was designed for. An indirect agent, by contrast, raises acetylcholine everywhere, which means it stimulates all receptor subtypes simultaneously. That broader reach is sometimes exactly what you want, as in Alzheimer’s treatment, and sometimes a source of unwanted side effects.
Why the Receptor Subtype Matters
Acetylcholine acts on two major receptor families. Muscarinic receptors sit on smooth muscle, glands, the heart, and certain brain regions. Nicotinic receptors sit at the junction between nerve and skeletal muscle, in autonomic ganglia, and throughout the brain. The two families respond to acetylcholine differently at a cellular level: muscarinic receptors work through slower, second-messenger cascades that can open or close ion channels depending on the subtype, while nicotinic receptors are themselves ion channels that snap open the instant acetylcholine binds.2PubMed. Cellular signaling mechanisms for muscarinic acetylcholine receptors
Five muscarinic subtypes (M1 through M5) and numerous nicotinic subtypes have been identified. Brain nicotinic receptors are increasingly recognized as contributors to the effects of nicotine and to the neuropathology of conditions like Alzheimer’s disease, Parkinson’s disease, and schizophrenia.3PubMed Central. Mammalian nicotinic acetylcholine receptors: from structure to function Nearly every clinical application of a cholinergic agonist can be understood through the lens of which receptor subtype the drug targets and where in the body that subtype is most concentrated.
Treating Dry Mouth and Dry Eyes in Sjögren’s Syndrome
One of the most common uses for direct muscarinic agonists is stimulating saliva and tear production in people with Sjögren’s syndrome, an autoimmune condition that attacks moisture-producing glands. Pilocarpine, a plant-derived muscarinic agonist, has been studied at doses of 20 to 30 mg per day and consistently increases both salivary flow and lacrimal secretion. In a placebo-controlled trial of 256 patients, pilocarpine significantly boosted salivary output from the very first dose, and patients reported meaningful improvements in dry mouth symptoms along with some relief of dry eyes at higher doses.4PubMed Central. Effectiveness of pharmacological interventions for Sjogren syndrome – A systematic review
Cevimeline, a newer muscarinic agonist with particular affinity for the M3 receptor found on salivary and lacrimal glands, offers a similar benefit. Patients taking 30 mg of cevimeline three times daily showed statistically significant improvements in their own assessment of dry eyes and dry mouth, along with objective increases in salivary and tear flow compared to placebo.5PubMed. A double-blind, randomized, placebo-controlled study of cevimeline in Sjögren’s syndrome patients with xerostomia and keratoconjunctivitis sicca A separate randomized trial confirmed these results, with both dosage groups reporting meaningful reductions in dry mouth symptoms and less need for artificial saliva.6Archives of Internal Medicine. Cevimeline for the Treatment of Xerostomia in Patients With Sjögren Syndrome: A Randomized Trial The most frequently reported side effects of both drugs, sweating, flushing, urinary frequency, and nausea, are predictable consequences of activating muscarinic receptors throughout the body, not just in the glands you are trying to stimulate.
Bladder Dysfunction and Glaucoma
Bethanechol is a direct muscarinic agonist used primarily for urinary retention and bladder underactivity. Because it is resistant to breakdown by cholinesterase, its effects last longer than acetylcholine’s would. Prescribing data show that the most common reasons for bethanechol use are bladder atony (about 35% of prescriptions), urinary retention (20%), neurogenic bladder (18%), and urinary incontinence (16%).7PubMed. Bethanechol: Is it still being prescribed for bladder dysfunction in women? The drug works by directly activating muscarinic receptors on the detrusor muscle, the muscle that contracts to empty the bladder.
In the eye, pilocarpine has a long history of use for glaucoma. It constricts the pupil and opens drainage pathways for the fluid inside the eye, lowering intraocular pressure. Animal research has shown that pilocarpine achieves pupil constriction not only by contracting the iris sphincter muscle but also by activating cholinergic receptors on nerve terminals in the iris dilator muscle. Those receptors suppress norepinephrine release, which relaxes the dilator and allows the sphincter to dominate.8PubMed. Inhibitory effect of pilocarpine on norepinephrine release from electrically stimulated iris dilator muscles of rabbits as a most possible mechanism of pilocarpine-induced miosis This dual mechanism helps explain why pilocarpine is particularly effective at constricting the pupil.
Myasthenia Gravis
Myasthenia gravis is an autoimmune disease in which antibodies attack nicotinic receptors at the neuromuscular junction, making skeletal muscles progressively weaker. Treatment typically begins with an indirect cholinergic agonist: pyridostigmine, an acetylcholinesterase inhibitor that raises acetylcholine levels at whatever functional receptors remain. Pyridostigmine has been used for over 50 years, is generally considered safe, and is recommended as first-line therapy despite a lack of large randomized controlled trials confirming its efficacy.9PubMed. Treatment of myasthenia gravis: focus on pyridostigmine
For people with mild, non-progressive disease, pyridostigmine alone may be enough to control symptoms. In more severe cases, it is used alongside immunosuppressive therapies that address the underlying autoimmune attack.10PubMed Central. A Practical Approach to Managing Patients With Myasthenia Gravis-Opinions and a Review of the Literature Because pyridostigmine raises acetylcholine levels broadly rather than only at skeletal muscle, its muscarinic side effects, including abdominal cramping, diarrhea, and excess salivation, are a practical limitation that patients and clinicians learn to manage through dose timing.
Alzheimer’s Disease
The cholinergic hypothesis of Alzheimer’s disease, the idea that degeneration of acetylcholine-producing neurons in the brain is a major driver of cognitive decline, motivated the development of centrally acting acetylcholinesterase inhibitors. Donepezil, galantamine, and rivastigmine are the three most widely prescribed. A systematic review and meta-analysis of placebo-controlled trials found that all three provide modest overall benefits for stabilizing or slowing decline in cognition, daily function, behavior, and global clinical status.11PubMed Central. Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer’s disease: A systematic review and meta-analysis
“Modest” is worth emphasizing. These drugs do not reverse Alzheimer’s or halt it entirely. They slow the trajectory, buying time in which patients retain more of their functional independence than they would without treatment. The benefits tend to be most noticeable in the early to moderate stages of the disease, and they come with a familiar set of cholinergic side effects: nausea, diarrhea, and sometimes a drop in heart rate.
Smoking Cessation and Nicotinic Partial Agonists
Nicotine itself is a cholinergic agonist, one that activates nicotinic receptors in the brain and triggers dopamine release in reward pathways. The pharmacological strategy for smoking cessation turns this relationship on its head. Varenicline is a partial agonist at the alpha-4-beta-2 nicotinic receptor, the subtype most responsible for nicotine’s rewarding effects. It stimulates the receptor enough to release roughly half the dopamine that nicotine would, easing withdrawal symptoms. At the same time, because it occupies the receptor with a relatively long half-life, it blocks nicotine from binding and delivering its full reward if the person smokes.12PubMed Central. Varenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherence
Cytisinicline, a related compound derived from a plant alkaloid, works through the same receptor. A matching-adjusted indirect comparison found that cytisinicline at standard doses showed no significant difference from varenicline in smoking cessation rates at 12 weeks, and may have an edge in maintaining longer-term abstinence out to 24 weeks.13PubMed Central. Comparative Effectiveness of Cytisinicline and Varenicline for Smoking Cessation: A Matching-Adjusted Indirect Comparison (MAIC) Both drugs represent an elegant use of partial agonism: activate the target just enough to calm the craving, but not enough to reproduce the addiction.
Common Side Effects and the Problem of Selectivity
Because acetylcholine is active in so many tissues, cholinergic agonists almost always produce effects beyond their intended target. The side-effect profile is predictable from the receptor biology:
- Muscarinic effects: excessive salivation, sweating, tearing, nausea, abdominal cramps, diarrhea, blurred vision, urinary urgency, and slowed heart rate.
- Nicotinic effects: muscle fasciculations, weakness at high doses, and, at the neuromuscular junction, paradoxical fatigue if too much acetylcholine accumulates and desensitizes the receptors.
Whether a drug crosses the blood-brain barrier determines whether it produces central nervous system effects like confusion, drowsiness, or vivid dreams. This is a key design consideration in drug development. Lipophilic (fat-soluble) compounds cross the barrier more readily than hydrophilic (water-soluble) ones. For bladder-targeted anticholinergics, the reverse side of this coin has been well studied: lipophilic agents like oxybutynin are more likely to cause brain-related side effects than a hydrophilic compound like trospium chloride.14PubMed Central. Anticholinergics for overactive bladder therapy: central nervous system effects The same principle applies in reverse to cholinergic agonists: when the goal is to reach the brain, as in Alzheimer’s treatment, the drug needs to be lipophilic enough to get there. When the goal is strictly peripheral, keeping the drug out of the brain reduces unwanted cognitive effects.
Cholinergic Agonists in Anesthesia
Anesthesiologists routinely use indirect cholinergic agonists to reverse neuromuscular blockade at the end of surgery. Drugs like neostigmine inhibit acetylcholinesterase at the neuromuscular junction, allowing acetylcholine to accumulate and restore muscle strength after a paralyzing agent wears off. The problem is that neostigmine has a narrow therapeutic range. Even at recommended doses of 15 to 50 micrograms per kilogram, it can cause both nicotinic effects, including upper airway muscle weakness and reduced inspiratory airflow, and muscarinic effects, including blurred vision, bronchial constriction, abdominal cramping, and nausea.15Neuropharmacology. The effects of acetylcholinesterase inhibitors on morbidity after general anesthesia and surgery To counteract the muscarinic side effects, anesthesiologists co-administer an anticholinergic like glycopyrrolate. This pairing illustrates a broader theme: many cholinergic agonist applications involve managing the drug’s unwanted receptor activation just as carefully as its desired effects.
Organophosphate Poisoning and the Cholinergic Crisis
The most extreme and dangerous form of cholinergic stimulation is organophosphate poisoning. Organophosphates, found in certain pesticides and weaponized as nerve agents, irreversibly inhibit acetylcholinesterase. Acetylcholine floods every synapse where it normally operates, producing a life-threatening cholinergic crisis: profuse secretions from every gland, pinpoint pupils, muscle fasciculations progressing to paralysis, slowed heart rate, bronchospasm, seizures, and altered consciousness.
Treatment relies on two complementary antidotes. Atropine, a muscarinic receptor blocker, counteracts the glandular and cardiac effects. Oximes like pralidoxime reactivate the inhibited acetylcholinesterase enzyme itself, restoring normal function. Research in rat models has shown that atropine and pralidoxime rescue distinct components of the poisoning: pralidoxime restores certain cardiovascular reflexes while atropine reverses heart-rate abnormalities, suggesting that using both together is more beneficial than either alone.16Toxicology and Applied Pharmacology. The antidotes atropine and pralidoxime distinctively recover cardiorespiratory components impaired by acute poisoning with chlorpyrifos in rats
Timing matters enormously. Once an organophosphate has been bound to acetylcholinesterase long enough, a chemical change called “aging” occurs: the enzyme loses a molecular fragment that makes it permanently resistant to reactivation by oximes.17PubMed Central. Efforts toward treatments against aging of organophosphorus-inhibited acetylcholinesterase Different organophosphate compounds age at different rates. The nerve agent soman ages within minutes, making rapid oxime administration critical, while others allow a longer window. Molecular modeling studies rank VX as the most harmful organophosphate nerve agent, with the oxime HI-6 performing best at freeing the enzyme, followed by obidoxime and pralidoxime.18PubMed. A molecular docking-based comparative assessment of various anticholinergic drugs as antidotes to different nerve agent poisoning Seizures in nerve agent exposure, which arise from overstimulation of central nervous system receptors, are controlled separately with benzodiazepines like diazepam, since atropine does not readily block nicotinic receptors in the brain.
Dietary Choline and Acetylcholine Levels
An interesting dimension most people never consider is that the raw material for making acetylcholine, choline, comes from your diet. Research dating back decades established that acetylcholine concentrations in the brain vary with dietary choline consumption. Rat studies showed that high-choline diets raised brain acetylcholine, and that this increase was additive with the effects of physostigmine, an acetylcholinesterase inhibitor, suggesting that eating more choline actually boosts acetylcholine synthesis rather than just saturating existing stores.19PubMed. Brain acetylcholine: control by dietary choline
Choline-rich foods include eggs, liver, soybeans, and certain fish. Whether increasing dietary choline meaningfully supplements the effect of a cholinergic drug in humans is less clear, but the connection is a reminder that the cholinergic system does not exist in pharmacological isolation. Your body builds acetylcholine from scratch using nutrients, and the supply of that building block influences how much of the neurotransmitter is available to begin with.
Allosteric Modulators and the Search for Selectivity
The biggest problem with traditional cholinergic agonists is their lack of selectivity. A drug that activates M3 receptors on salivary glands also activates M3 receptors in the gut, producing nausea and diarrhea. An acetylcholinesterase inhibitor that raises acetylcholine at the neuromuscular junction also raises it in the heart and the lungs. Researchers have spent years trying to engineer selectivity into cholinergic drugs, and the most promising recent avenue is allosteric modulation.
Rather than binding to the same site as acetylcholine (the “orthosteric” site, which is highly conserved across receptor subtypes and therefore hard to target selectively), allosteric modulators bind to a different spot on the receptor and change how it responds to acetylcholine. This approach has shown particular promise for muscarinic M1 and M4 receptors, subtypes concentrated in brain regions involved in cognition and psychosis. The discovery of subtype-specific allosteric modulators has advanced understanding of how these receptors contribute to schizophrenia and opened potential paths toward treatments that could improve cognitive symptoms without the sweating, nausea, and heart-rate changes that plague conventional muscarinic agonists.20PubMed Central. Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia
Several M1/M4-targeted compounds have entered clinical trials for schizophrenia, and the early results have generated real excitement. If these drugs work as hoped, they would represent a shift in psychiatric treatment: targeting the cholinergic system rather than (or alongside) the dopamine pathways that current antipsychotics focus on. The evidence is still maturing, but the concept has gone from speculative to plausible in under a decade.